Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 3/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545595 | 0.90 | CDC25B (0.45) | IDO1GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL1415184 | 0.89 | GABRP (0.44) | GRM6ALDH1A1HSD17B10CDC25BGABRP | |
| SCHEMBL27492828 | 0.85 | GABRA1 (0.43) | GRM6ALDH1A1HSD17B10GABRPGABRD | |
| SCHEMBL1415186 | 0.83 | NR4A1 (0.44) | GRM6ALDH1A1HSD17B10CDC25BGABRP | |
| SCHEMBL14627192 | 0.82 | AR (0.41) | ALDH1A1HSD17B10CDC25BGABRPGABRD | |
| SCHEMBL5373294 | 0.81 | IDO1 (0.45) | IDO1HSD17B10CDC25BGABRPGABRD | |
| SCHEMBL31758437 | 0.81 | ALDH1A1 (0.61) | IDO1EP300KAT8ALDH1A1HSD17B10 | |
| SCHEMBL4685498 | 0.81 | ALDH1A1 (0.61) | IDO1EP300KAT8ALDH1A1HSD17B10 | |
| SCHEMBL1025155 | 0.80 | IDO1 (0.47) | IDO1EP300KAT8HDAC3KAT2B | |
| SCHEMBL22545599 | 0.80 | AAK1 (0.44) | ALDH1A1GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114173772-A | Inhibitors of CD40-CD154 binding | 托尼克斯医药控股公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3952853-A1 | INHIBITORS OF CD40-CD154 BINDING | Tonix Pharmaceuticals Holding Corp. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | disclosed |
| CN-101772506-B | Macrocycles and their uses | NOVARTIS AG | 2014-02-12 | — | — | CN | disclosed |
| CN-101772506-A | Macrocylc compound and uses thereof | NOVARTIS AG | 2010-07-07 | — | — | CN | disclosed |
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | disclosed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | IDO1 1535/4885GRM6 799/4885EP300 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.